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Haploidentical hematopoietic stem-cell transplantation is an alternative transplant strategy for patients without an HLA-matched
donor. Still, only half of patients who might beneﬁt from transplantation are able to ﬁnd an HLA-matched related or unrelated
donor. Haploidentical donor is readily available for many patients in need of immediate stem-cell transplantation. Historical
experience with haploidentical stem-cell transplantation has been characterised by a high rejection rate, graft-versus-host disease,
and transplant-related mortality. Important advances have been made in this ﬁeld during the last 20 years. Many drawbacks of
haploidenticaltransplantssuchasgraftfailureandsigniﬁcantGVHDhavebeenovercomeduetothedevelopmentofnewextensive
T cell depletion methods with mega dose stem-cell administration. However, prolonged immune deﬁciency and an increased
relapse rate remain unresolved problems of T cell depletion. New approaches such as partial ex vivo or in vivo alloreactive T
cell depletion and posttransplant cell therapy will allow to improve immune reconstitution in haploidentical transplants. Results
of unmanipulated stem-cell transplantation with using ATG and combined immunosuppression in mismatched/haploidentical
transplant setting are promising. This paper focuses on recent advances in haploidentical hematopoietic stem-cell transplantation
for hematologic malignancies.
1.Introduction
Hematopoietic stem-cell transplantation (HSCT) oﬀers a
curative treatment for many patients with malignant and
nonmalignant hematologic disorders. As the probability of
ﬁnding an HLA identical sibling donor is only 25% to 30%,
attention has been focused on the use of alternative donors,
either from unrelated adult donors, umbilical cord blood,
or partially matched related donors. Currently, the chance
of ﬁnding a matched unrelated donor varies from 60%–
70% for Caucasians to less than 10% for ethnic minorities
[1, 2]. Further drawbacks for a patient who urgently needs a
stem-celltransplantationarethetimeintervalfrominitiating
an unrelated donor search to the identiﬁcation of an
appropriate donor of about 4 months [3], the considerable
costs of high-resolution HLA typing, registry, and banking
expenditures, and the absence of donor registries in many
countries worldwide. Unrelated cord blood has become a
new promising stem-cell source due to its faster availability,
tolerance of 1-2 HLA mismatches out of 6, lower incidence
and severity of acute graft-versus-host disease (GVHD),
and lack of risk to the donor. However, the limited unit
size, high incidence of posttransplant infections, and slow
immune recovery are obstacles to its broader application
especially in adult patients [4, 5]. Haploidentical related
donor transplantation has been developed to address limi-
tations in allogeneic transplant donor availability. Virtually
all patients have a one haplotype-mismatched donor. In
addition to immediate availability, haploidentical donors
have several advantages such as (a) ability to select the best
donor on the basis of age, sex, and infectious disease status,
(b) optimal graft composition, and (c) prompt access to2 Bone Marrow Research
repeated donation in case of graft failure or need for cellular
therapy after transplant. The initial studies of haploiden-
tical HSCT employed myeloablative conditioning regimen
followed by infusion of unmanipulated bone marrow grafts,
and GVHD prophylaxis with methotrexate (MTX), with
or without cyclosporine (CSA) [6–8]. Outcome of these
transplants was poor due to high rate of graft failure, severe
GVHD, and nonrelapse mortality (NRM), especially when
donors were mismatched for 2 or more antigens. Over the
past decade results of haploidentical HSCT have improved
signiﬁcantly due to novel graft manipulation techniques,
improved prophylaxis of GVHD, and the development of
new conditioning regimens. This paper focuses on recent
developments which have led to more encouraging results in
haploidenticalHSCTformalignantdiseasesinadultpatients.
2. EarlyExperience with Haploidentical Bone
MarrowTransplantation
In 1983, Powles et al. [9] reported the outcome of 35 pa-
tients with acute myeloid or lymphoblastic leukaemia who
received a 1–3 HLA-mismatched marrow grafts from parent,
child, or sibling, following cyclophosphamide/total body ir-
radiationorcyclophosphamide/melphalanconditioningreg-
imens.Therewere11patientssurvivingat6monthsandonly
5 patients more than 2 years. Graft failure occurred in 29%
of patients and GVHD in 80% of patients. The poor survival
rate with nonrelapse mortality occurring in more than half
of the patients was discouraging.
In the late 1980s, the Seattle group reported the results
of HLA-mismatched/haploidentical transplantation using
unmodiﬁed bone marrow and myeloablative conditioning
in patients with haematological malignancies [6–8]. They
demonstrated that the probability of survival for patients
who underwent transplantation from an HLA 1-locus-mis-
matched family member was similar to that for patients
who received a graft from an HLA-identical sibling, while
results of transplantation from 2 or 3 loci-mismatched
family member were extremely poor, owing to the high inci-
dence of graft failure and severe GVHD. The results of
these early studies were disappointing and highlighted the
inherent diﬃculties of haploidentical transplantation using
unmodiﬁed bone marrow and limited its application to
many patients who could beneﬁt from transplantation.
3. HaploidenticalTransplantationwith
P a r t i a lE xV i v oT - C e l lD e p l e t i o nC o m b i n e d
with IntensiveImmunosuppression.
Starting in the early 1990s, several investigators set to work
on strategies to overcome HLA barriers and control GVHD
in haploidentical transplantation through partial depletion
of bone marrow combined with intensive immunosuppres-
sion [10–12]. In these studies, the incidence of grade 2–4
acute GVHD has ranged from 18% to 40% in patients of
HLA-mismatched bone marrow transplantation after T-cell
depletion using anti-CD6 or T10B9 monoclonal antibodies.
Henslee-Downeyetal.[12]intheirpioneeringworkused
marrow grafts depleted with T10B9 monoclonal antibodies
combined with intensive posttransplant immunosuppres-
sion with CSA, ATG, and methylprednisolone in 72 patients
mainly aﬀected by hematologic malignancies following TBI-
based myeloablative conditioning. Thirteen patients received
1 antigen, 35 patients 2 antigen, and 24 patients 3 antigen
mismatched grafts. The probability of initial engraftment
was 88%, and it was 96% following second transplantation.
Importantly, the incidence of grade 2–4 or 3-4 acute GVHD
was 16% and 7%, respectively. Chronic extensive GVHD
occurred in 4 of 48 (8%) evaluable patients. In all, the
probability of 2 year survival was 35%, and it was 55% for
low-risk patients. Relapse occurred in 32% of patients.
Recently, investigators from the same institute have
reported the outcome on 201 patients with acute leukaemia
(67% not in remission) who received marrow grafts from
partially mismatched related donors (92% mismatched for
2-3 HLA antigens) [13]. Conditioning regimen consisted
of TBI, cyclophosphamide, cytarabine, etoposide, ATG, and
methylprednisolone. GVHD prophylaxis comprised partial
T-cell depletion with OK3 or T10B9, steroids, ATG and
cyclosporine. Impressively, the cumulative incidence of
grades 2–4 acute GVHD and chronic GVHD were 13%
and 51%, respectively. However, the probabilities of OS and
DFS at 5 years were low (19% and 18%, resp.). OS and
DFS probabilities were better in patients transplanted in
remission (34% and 29%, resp.). The cumulative incidence
of relapse at 5 years was 31%. Transplant-related mortality
was 51%. Patient age >15 years, active disease at transplant,
donor age >25 years, and 3-antigen mismatches aﬀected the
outcome adversely, emphasizing the importance of patient
selection and disease status for good outcome.
4. HaploidenticalT-Cell Depleted
TransplantationUsing CD34+Selection
ThemoderneraofhaploidenticaltransplantationviaCD34+
selection started with clinical studies by the Perugia Uni-
versity transplant team from Italy. They developed a new
approach to ex vivo T-cell depletion with a “mega dose”
stem cells following myeloablative TBI-based conditioning
regimen. The concept of mega dose of stem cells came from
animal models, where higher doses of stem cells overcame
major histocompatibility barrier (MHC), by presumed “veto
eﬀect” [14, 15].
In their pioneering work, Aversa et al. [16] transplanted
mega doses of stem cells obtained from bone marrow and
G-CSF-stimulated peripheral blood following T-cell deple-
tion with soybean agglutination and E-rosetting technique,
without any subsequent GVHD prophylaxis in 17 patients
with end-stage leukemia. One patient had rejection, and
all the remaining patients achieved sustained engraftment.
One patient died from grade 2 acute GVHD, and no other
patients developed grade ≥2a c u t eG V H D .R u g g e rie ta l .[ 17]
from the same team showed that killer immunoglobulin-
like receptor (KIR) mismatching in the GVH direction isBone Marrow Research 3
associated with strikingly less relapse following transplanta-
tion for AML patients although such eﬀect was not observed
in ALL patients. The Perugia team subsequently adopted
new depletion technique with the E-rosetting followed by
CD34-positive selection using Ceprate [18], or positive se-
lection of CD34 cells from peripheral blood by magnetic
beads using the CliniMACS (Myltenyi) system [19]. The
development of T-cell depletion method using CliniMACS
system, by the investigators from Tuebingen, Germany, has
revolutionized the ﬁeld of haploidentical transplantation
w h i c hp r o v i d e sag o o dy i e l do fC D 3 4 +c e l l sw i t hT - c e l l
depletion of more than 4 logs and B-cell depletion of over
3l o g s[ 20], thus also allowing to lower the incidence of EBV-
associated lymphoproliferative disorders usually frequent in
extensive T-cell deleted mismatched transplantation. Apart
from eﬀective T-cell depletion, this automated graft pro-
cessing system provides reproducible CD34 yield and allows
to perform T-cell-depleted haploidentical transplantation in
any transplant center.
In a phase II trial, the Perugia team has reported results
of HLA-haploidentical transplants for adults with high risk
acute myeloid (n = 67) or lymphoid leukemia (n = 37)
[19]. Conditioning regimen consisted of 8Gy TBI, thiotepa,
ﬂudarabine and ATG with no GVHD prophylaxis after
transplantation.PBSCgraftconsistedofCD34+cellsselected
using the CliniMACS one-step procedure in 88 donors and
the Isolex two-step procedure (positive selection of CD34+
cells followed by negative selection of CD3+ cells) in 16
donors. Median CD34+ cell dose was 13.8 × 106/kg, and it
was 1 × 104/kg for CD3+ cells. Ninety-four (91%) of 101
evaluable patients achieved primary engraftment. Rejection
o c c u r r e di n7( 7 % )p a t i e n t s .A c u t eg r a d e2o rg r a d e3 - 4
GVHD developed in 6 and 2 patients, respectively. Extensive
chronic GVHD occurred in 3 patients. High TRM (40%)
occurred mostly from infection was probably anticipated,
given that many patients were heavily pretreated and had
advanced disease status at transplantation. The cumulative
incidence of relapse was 16% in patients transplanted in
remission and 51% in those transplanted in relapse. Relapse
was less frequent (14%) in AML patients receiving graft
from NK-alloreactive donors then patients whose donor
was not NK-alloreactive (28%) although the diﬀerence was
not statistically signiﬁcant. Two-year probability of EFS
in 42 AML and 24 ALL patients receiving transplant in
any complete remission was 48% ± 8% and 46% ± 10%,
respectively. However, patients transplanted in relapse had
only 4% of EFS probability.
In a recent multicenter registry-based study, Ciceri
et al. [21] reported on 266 adult patients with de novo
acute leukemia who received haploidentical transplanta-
tion. The conditioning regimen was similar to the Perugia
protocol. This study conﬁrmed that a high engraftment
rate and minimal GVHD in the absence of any posttrans-
plant immunosuppression after HSCT from haploidentical
donors can be achieved by infusion a large number of
CD34+ selected cells. Leukemia-free survival at 2 years was
48% ± 10%,21% ±5%,and1%forpatientswithAMLwho
received transplantation in CR1, ≥CR2, and nonremission.
In ALL patients, the same probabilities were 13% ± 7%,
30% ± 8%, and 7% ± 5%, respectively. As in the Perugia
experience, TRM, mostly from infection, was observed in
a signiﬁcant proportion of patients indicating that fast
immune recovery is essential for successful transplant out-
come.
In a Canadian multicenter study [22], the outcome
of haploidentical transplantation in 11 patients with AML
who received CD34+ selected grafts following a modiﬁed
Perugia protocol was reported. All patients had sustained
engraftment, and none developed GVHD. However, death
from relapse or infection occurred in 10 of the 11 patients
highlighting that delayed immune reconstitution leading to
high infection-related mortality remains a major obstacle in
haploidentical transplants.
Kato et al. [23] from Japan have reported a nationwide
survey of the outcome of haploidentical transplantation on
135 patients following CD34+ selected from bone marrow
or GCSF-mobilized PBSC grafts using the Isolex device.
Twenty-eight donors were mismatched for 0-1 antigen, 64
for 2, and 43 for 3 antigens. Thirty-eight patients received
CD34+ selected cells from bone marrow, 74 patients from
PBSC, and 23 patients from both. TBI-based conditioning
regimen was used in 104 of 110 patients with malignancy.
ATG was given to 47 patients. Posttransplant GVHD pro-
phylaxis with CSA, tacrolimus, MTX, or steroids either
alone or in combination was given to 105 patients. The
median CD34+ cell dose was lower than that used the
Perugia group: 3.2 × 106/kg, for patients receiving bone
marrow, 5.5 × 106/kg for patients receiving PBSC, and
4.9 × 106/kg for those receiving both. The median CD3+
cell dose was: 6.0 × 104,9 . 4× 104, and 12.1 × 104 for
BM, PBSC, and BM + PBSC groups, respectively. Graft
failure occurred in 13% of patients with malignancies and
40% in nonmalignant diseases. Importantly, the incidence
of grade 3 acute GVHD was low 8.4%, and no patient
developed grade 4 acute GVHD. Disease-free survival at 5
years was 39% in standard risk and 5% in high risk patients,
similar to those observed in other studies of haploidentical
transplantation. The results of this study show that standard
dosesofCD34+cellsprobablyarenotsuﬃcientforsustained
engraftment in nonmalignant diseases and posttransplant
immunosuppression could be necessary to prevent severe
GVHD in haploidentical transplants with moderate degree
of T-cell depletion.
5. HaploidenticalTransplantation Using
CD3/CD19 Depletion
Investigators from Tuebingen, Germany, used mega dose
of positive CD34+ selected grafts from HLA-mismatched
parental donors following myeloablative conditioning reg-
imen which resulted in high transplant-related mortality
[24]. Consequently, they adopted a new regimen using
graft CD3/CD19-depleted with anti-CD3-and anti-CD19-
coated microbeads on a CliniMACS device. Such grafts not
only contain CD34+ stem cells but also CD34 negative
progenitors, natural killer cells, and dendritic and graft-
facilitating cells which could enhance engraftment and4 Bone Marrow Research
fast immune recovery after transplantation. The use of
CD3/CD19 depleted grafts following a reduced intensity
conditioning regimenwasproposed asanalternativetoover-
come negative consequences of myeloablative conditioning
regimen with CD34+ positive selection.
Lang et al. [25] in a pilot study of 11 children with
hematologic malignancies used CD3/CD19 depleted grafts
following a reduced intensity conditioning (RIC) regimen
consisting of ﬂudarabine, melphalan, and thiotepa; primary
engraftment rate was 91% with faster CD3+ T-cells reconsti-
tution as compared with patients who received CD34+ and
CD133+ selected grafts.
Recently, Bethge et al. [26] reported results of haploiden-
tical transplantation on 29 adult patients with hematologic
malignancies (AML = 16, ALL = 7, NHL = 3, MM = 2,
CML = 1) who received CD3/CD19 depleted grafts following
a RIC regimen consisting of ﬂudarabine, thiotepa, mel-
phalan, and OKT-3. Fifteen patients had relapse following
previous allogeneic or autologous transplantation, and the
remaining patients had refractory disease. Posttransplant
immunosuppression with mycophenolate mofetil was used
if CD3+ cell dose in the graft exceeded 5 × 104/kg. The
CD3/CD19 depleted grafts contained a median of 7.6 ×
106/kg CD34+cells/kg, 4.4 × 104 CD3+cells/kg, and 7.2 ×
107 CD56+cells/kg. All but one patient engrafted. Grade
2–4 GVHD occurred in 48% of patients. Twenty of 29
patients (68%) died, 12 from relapse, 7 from infection, and
1 from GVHD. The probability of EFS at 12 months was
35%. Results of this study demonstrate that HSCT with
CD3/CD19 depleted grafts without mega dose of CD34+
cellsisfeasible,safeandresultedinanacceptablesurvivalrate
in heavily pretreated higher risk patients.
In a prospective multicenter phase II study of haploiden-
tical HSCT in 60 adults (including patients reported in
the previous study) with hematologic malignancies using
RIC and CD3/CD19 depleted grafts Ferdermann et al.
[27] reported clinical outcomes and immune reconstitution.
Patients were treated with the same conditioning regimen as
reported by Bethge et al. [26]. At transplantation 30 patients
were in CR and 30 in partial remission. Grafts contained
median of 6.8 × 106 (range 3.5–22) CD34+cells/kg, 4 ×
104 (range, 0.9–44) CD3+cells/kg and 2.8 × 107 (range
0.00–37.3) CD56+cells/kg. The incidence of grade 2–4 acute
GVHD and chronic GVHD was 47% and 15%, respectively.
The probability of survival at 1 and 2 years were 41% and
24%, respectively. Overall nonrelapse was high 44%. There
was no positive impact of KIR-mismatch on survival even in
the subgroup of patients with AML. Recovery of NK cells
was early and fast. Although T- and B-cell reconstitution
was delayed, it seemed faster compared with CD34+ selected
transplants.
Recently this group has reported results of immune
reconstitution after haploidentical HSCT using RIC and
CD3/CD19 depleted grafts in 28 patients [28]. Engraftment
was rapid and sustained without mega doses of CD34+ cells
with full chimerism reached on day +15 after transplan-
tation. Large amount of NK cells resulted in fast NK-cell
recovery. T- and-B-cell reconstitution was delayed but was
fasterthanreportedafterCD34+selectionandmyeloablative
conditioning. These data show that despite relatively fast
immunereconstitutionfollowingCD3/CD19-depletedgrafts
nonrelapse mortality remains still high at least in adult
patients.
6.PosttransplantHigh-Dose
Cyclophosphamide for Selective In Vivo
T-Cell Depletion
It has been shown in animal models that both graft rejection
and GVHD after histoincompatible BMT can be inhibited by
the posttransplant administration of high-dose cyclophos-
phamide, which is known to be highly toxic to lymphocytes
proliferating in response to recent antigen stimulation [29].
Based on this experience, investigators from Johns Hopkins
ﬁrst demonstrated the feasibility of unmanipulated bone
marrow transplantation from haploidentical related donors
after nonmyeloablative conditioning regimen, followed by
posttransplant high-dose cyclophosphamide in thirteen
patients with high risk malignancies [30]. Conditioning
regimen consisted of ﬂudarabine and low-dose TBI in 3
patients (cohort 1), while the remaining 10 patients also
received cyclophosphamide 29mg/kg in two days (cohort
2). All patients received cyclophosphamide 50mg/kg on day
3 and mycophenolate mofetil and tacrolimus from day 4
onward after transplantation. Two patients (both in cohort
1) rejected their grafts; grade 2 or 3 acute GVHD occurred in
6 patients. Six out of 10 patients in cohort 2 were alive, and
5 of them in complete remission. Updating their experience,
Luzniketal.[31]reportedtransplantoutcomesof68patients
who received a haploidentical nonmyeloablative bone mar-
row transplant for hematologic malignancies using high-
dose posttransplant cyclophosphamide at Johns Hopkins or
Fred Hutchinson Cancer Research Center. Nonmyeloablative
conditioning regimen consisted of ﬂudarabine, cyclophos-
phamide, and TBI. As GVHD prophylaxis, they received
posttransplant cyclophosphamide on day 3 or days 3 and
4 and tacrolimus and mycophenolate mofetil starting day 5
after transplantation. Low incidence of acute GVHD (grades
2–4, 34% and grades 3-4, 6%) and nonrelapse mortality at
1 year (15%) with this new approach are very encouraging
although there were a relatively high incidence of graft
rejection (13%) and relapse rate at 1 year (51%).
7.MyeloablativeTransplantationUsing
InVivoT-Cell Depletion
The ﬁrst study of haploidentical transplantation from
mother to child in advanced leukaemia using busul-
fan/cyclophosphamide conditioning along with in vivo T-
cell depletion with antilymphocyte globulin given before
and after unmanipulated bone marrow transplantation was
reported by the Pesaro group, Italy, in 1995 [32]. The
probability of event-free survival and relapse was 26% and
33%, respectively. Severe acute GVHD occurred in 32% of
patients. Although results were similar to those obtained in
advanced leukaemia after HLA identical sibling transplantsBone Marrow Research 5
at the same institution, the data showed that rejection
and severe GVHD remained high despite post transplant
serotherapy.
Recently Lu et al. [33] from China reported results of
HLA mismatched/haploidentical transplantation using G-
CSF- primed bone marrow and peripheral blood with inten-
sive immunosuppression including antithymocyte globulin
(ATG) for in vivo T-cell depletion. Conditioning regimen
consisted of cytosine arabinoside, busulfan, cyclophos-
phamide, and semustine, while GVHD prophylaxis included
CSA, mycophenolate mofetil, and a short-course of MTX.
In this study, they compared the clinical outcomes in
HLA-haploidenticaltransplantationtoHLA-identicalsibling
transplantation without ATG. The cumulative incidence
of grades 2–4 GVHD in the matched and mismatched
cohorts were 32% versus 40% (p = NS), respectively. The
incidence of chronic GVHD was similar in both groups.
Surprisingly, treatment-related mortality and relapse rate
were similar (14% versus 22% and 13% versus 18%, resp.)
in both cohorts of patients. Updating the observations
of this group to 250 patients [34] who underwent HLA-
mismatched/haploidenticaltransplantation,the3-yearprob-
ability of leukemia-free survival in standard and high-risk
acute myeloid leukemia was 70.7% and 55.9%, and in acute
lymphoblastic leukemia, the respective probabilities were
59.7% and 24.8%. The incidence of acute GVHD grades
2–4 was 45.8%, and it was 13.4% for grade 3-4 GVHD.
Although the overall incidence of chronic GVHD was 42.4%,
its extensive form was only 14.3%. In this study, the low
incidence of severe acute and chronic GVHD among the
mismatched cohort is impressive and in part may be related
to the use of ATG providing in vivo depletion of T-cells and
combined posttransplant immunosuppression.
Another approach to in vivo depletion is the use
of alemtuzumab, a humanized monoclonal antibody that
targets CD52 antigen that is expressed on many T and B
cells as well as on some dendritic and NK cells. Kanda et al.
[35] reported the clinical outcomes of haploidentical trans-
plants in six patients treated with alemtuzumab combined
with conventional TBI and cyclophosphamide and GVHD
prophylaxis with CSA + short MTX for patients aged <50
years old. All six patients achieved engraftment, and only
onepatientdevelopedacuteGVHD,and2patientsdiedfrom
disease recurrence.
8. Reduced IntensityTransplantationUsing
InVivoT-CellDepletion
Historically transplant-related mortality was high in patients
receiving mismatched transplantation following myeloabla-
tive conditioning. Therefore, several transplant teams have
explored reduced intensity transplants in this setting.
Rizzierietal.[36]reportedoutcomesofreducedintensity
haploidentical transplants for 49 patients who received
ﬂudarabine, cyclophosphamide, and alemtuzumab as condi-
tioning regimen and mycophenolate mofetil with or without
CSA for GVHD prophylaxis. Importantly, the incidence of
grade 2–4 or 3-4 acute GVHD was 16% and 8%, respectively,
and treatment related mortality was 10.2%. Primary or
secondary graft failure occurred in 6% and 8% of patients,
respectively. The 1 year survival was 31% for all patients and
63% for patients in standard risk group.
Recently, Ogawa et al. [37] from Osaka University,
Japan, reported outcomes of haploidentical transplants in 26
patients with high-risk hematologic malignancies following
reduced intensity transplantation of PBSC. Conditioning
regimenconsistedofATG,ﬂudarabine,busulfan,andGVHD
prophylaxisconsistedoftacrolimusandmethylprednisolone.
There was one rejection, and the incidence of grade 2–4
acute GVHD was only 19%. Four patients (15%) died of
treatment-related complications, and six (23%) of progres-
sive disease. Sixteen patients (62%) were alive in complete
remission. These data are encouraging in terms of survival
and transplant-related mortality although limited to small
number of patients.
I nar e c e n ts t u d yf r o mJ a p a nK u r o k a w ae ta l .[ 38]
have reported on 66 patients treated with reduced intensity
conditioning regimen consisting of TBI or ﬂudarabine,
ATG, busulfan, and melphalan. GVHD prophylaxis included
tacrolimus ± methylprednisolone. Fifty patients received
PBSCandtwelvepatientsbonemarrow.Fourpatients(6.1%)
had rejection. Twenty three (38%) out of 60 evaluable
patients developed acute grade 2–4 GVHD. Seven patients
(12%) had relapse. Transplant-related mortality at 2 months
was high 70%. Organ failure and infections were the main
causes of mortality in 38 out of 46 patients. Overall survival
was much worse for 28 patients who received HLA 3 loci
mismatched grafts than for 11 patients receiving 1 locus
mismatched grafts (12.5% versus 63.6%, resp.). Results of
haploidentical transplants in this study were unsatisfactory
as compared with previous study from the same country.
Probably low dose of ATG, its timing, and the use of
melphalan in the conditioning are responsible for inferior
results as compared with the previous study by Ogawa et al.
[37].
9. Haploidentical Transplantation after
ExVivoInductionof Anergy
Although nonselective T-cell depletion combined with high
CD34+ cell doses has been eﬀective in ensuring a high
rate of sustained engraftment and preventing severe GVHD
in haploidentical transplants, the success of this strategy is
limited by increased infectious complications, high relapse
rate associated with delayed immune reconstitution, and loss
of pathogen- and tumor-speciﬁc T-cells. Therefore, various
experimental strategies to selectively deplete alloreactive T-
cells within the graft to prevent GVHD while preserving
pathogen- and tumor-speciﬁc immunity have been devel-
oped in an attempt to improve immune reconstitution
after HLA-mismatched transplantations [12, 13]. Induction
of allospeciﬁc anergy in donor T-cells before HSCT is an
alternative to selective depletion. Activation of T-cells occurs
through the engagement of both T-cell receptor and CD28
on the surface of T-cells by the MHC peptide and B7 family
molecules on antigen presenting cells (APCs). Blockade of6 Bone Marrow Research
T-cell receptor signalling by fusion proteins (CTLA4-Ig) or
monoclonal antibodies (anti-B7) that bind to the CD28
ligands B7 on APC lead to an anergy state [39]. In a
recent study, Davies et al. [40] reported on 24 patients with
hematologic malignancy (n = 21) or bone marrow failure
syndromes (n = 3) who received haploidentical transplants
by inducing T-cell anergy with CTL4-Ig or anti B7.1 and
B7.2 antibodies. Patients received TBI-based conditioning
regimen and CSA and short MTX as GVHD prophylaxis.
Two patients had rejection, and two other patients died
early before engraftment occurred. Only 5 (24%) of 21
evaluable patients developed severe GVHD. The incidence
of chronic GVHD was low 8%. Twelve (50%) patients died
of TRM. Actuarial EFS at 10 years was 33%. Importantly,
the cumulative incidence of relapse/progression was low
17% although 14 patients had progressive disease at the
time of transplantation indicating preserved graft-versus-
tumor eﬀect following such transplantation. Patients had
rapid immune reconstitution, and there was no mortality
from viral infections. Although high early TRMsv is mainly
due to sepsis and multiorgan failure, results of this study
are promising, suggesting that alloanergized BMT could be
an alternative to nonselective T-cell-depleted haploidentical
transplants especially in hematologic malignancies.
10. Major Complications of
HaploidenticalTransplantation
Recent advances with eﬀective T-cell depletion and inten-
sive conditioning regimen have signiﬁcantly reduced the
incidence of both GVHD and rejection after haploidentical
transplantation for hematologic malignancies. Furthermore,
development of reduced intensity conditioning regimen
in haploidentical transplants resulted in reducing early
transplant-related mortality and GVHD, while enabling
sustained engraftment, and hence allowing for medically
less-ﬁt patients to beneﬁt from haploidentical transplan-
tation. However, posttransplant infectious complications
and relapse remain the most important barriers yet to be
overcome in this setting. Eﬀective T-cell depletion in adults
is associated with a profound and prolonged immunodeﬁ-
ciency that predisposes patients to life-threatening infections
and, in the absence of donor lymphocyte mediated graft-
versus tumor eﬀect, to leukaemia relapse, both representing
leading cause of death in this treatment approach.
In a recent study by Aversa et al. [19], nonrelapse mortal-
ity occurred in 28 (36.5%) patients and 27 of them died from
infections with cytomegalovirus as the leading cause (52%)
followed by fungal infections (19%). Although the incidence
of adenovirus infection is low in adult patients than in
children, it is still a signiﬁcant cause of nonrelapse mortality
in haploidentical transplants. Epstein-Barr virus reactivation
isafrequenteventafterT-celldepletedstem-celltransplanta-
tion due to the lack of donor-derived EBV-speciﬁc cytotoxic
T-cells in the early period after transplantation which is
a risk factor for the development of lymphoproliferative
disorders. Intensive screening for these viruses in pre- and
posttransplant period and timely use of preemptive antiviral
agents (ganciclovir or foscarnet for CMV and cidofovir
for adenovirus) or monoclonal antibodies (rituximab for
EBV) can prevent progression in disease in most patients.
However, in profound immunodeﬁcient patients, even with
preemptive therapy, it is diﬃcult to obtain long-lasting
control of infection/disease. Therefore, approaches such as
adoptivetransferofdonor-derivedCMV,adenovirusorEBV-
speciﬁc T-cells may help to protective immunity in the
early post transplant phase, and hence reduce nonrelapse
mortality in haploidentical transplants. Over the past decade
there has been considerable progress in generating nonal-
loreactiveT-cellsspeciﬁcagainstdiﬀerentpathogensasCMV,
adenovirus,EBV andaspergillusspecies. Leen et al.[41]h a v e
evaluated eﬃcacy of generated antigen speciﬁc cytotoxic T
lymphocytes (CTL) against CMV, adenovirus and EBV in
immunocompromisedrecipients.DoserangeofCTLwas5×
106 to 1.35 × 108/m2. Twelve patients received bivirus and 15
patientstrivirusCTL.Nodoselimitingtoxicitywasobserved.
Most patients showed decreasing or clearance of viral load.
Although very promising results, these approaches require
high resources and are characterized by speciﬁc intrinsic
limitations that prevent a widespread use.
Leukemia relapse is another common complication
occurring in haploidentical T-cell depleted transplants. The
cumulative incidence of relapse was 16% in patients trans-
planted in remission and 51% in those transplanted in
relapse [19]. Eight patients were given rescue therapy for
relapse(DLIin5,secondtransplantin2,andDLI/imatinibin
onepatient),whilein18patientsrapidprogressionofdisease
precluded any rescue treatment. The only ALL/Ph+ patient
treated with DLI/imatinib was alive in remission. Dismal
outcome after haploidentical T-cell depleted transplants in
relapse indicates that for these patients alternative strategies
should be considered.
11. Approaches to Overcome Drawbacks of
HaploidenticalT-Cell-Depleted
Transplantation
To overcome limitations of haploidentical T-cell depleted
transplantation, hence enabling physician to perform safe
and more successful transplants, much eﬀorts have been
made in selecting the best donor and/or developing immu-
nological modulation after transplantation.
11.1. Role of NIMA-Mismatched Haploidentical Transplants.
Bidirectional fetomaternal hematopoietic cell traﬃcking
during pregnancy can lead to long-lasting microchimerism
which can have a beneﬁcial eﬀects on transplantation
outcome by reducing host-versus-graft or graft-versus-host
alloreactivity not only against noninherited maternal anti-
gens(NIMA)butalsoagainstnoninheritedpaternalantigens
(NIPA) in the setting of stem-cell transplantation [42, 43]. In
a large IBMTR analysis, van Rood et al. [44] ﬁrst showed a
low rate of acute GVHD and TRM in sibling who received
T-cell replete bone marrow transplantation mismatched
for NIMAs compared with those mismatched for NIPAs,
suggesting the presence of immunological tolerance againstBone Marrow Research 7
NIMAs in haploidentical transplants. Several studies from
JapanhaveconﬁrmedthetolerizingeﬀectofNIMAs[45,46].
However, despite relatively low incidence of acute GVHD
in NIMAs-mismatched transplants, the incidence of chronic
extensive GVHD is still high in such T-cell replete approach
[47] indicating that presumed immunologic tolerance alone
is not suﬃcient to signiﬁcantly reduce GVHD and improve
transplant outcomes.
11.2. Role of NK Cell Alloreactivity and NK Cell Infusion
in Haploidentical Transplants. It has been suggested that
NK cell alloreactivity is a powerful tool against leukemic
cells, allowing an eﬀective antileukemic activity following
haploidentical HSCT, especially in AML patients. KIR-ligand
incompatibility in GVH direction has been associated with
lower relapse rate and improved leukemia-free survival
in adult patients with AML who received transplant in
remission [48]. However, patients who are not in remission
have a substantially high risk of relapse or progression,
probably due to an immune escape from the selective
pressure of donor T-cells owing to the loss of the patient-
speciﬁc HLA haplotypes with the frequency of 30% [49].
As KIR-ligand mismatch could exert antirelapse activity,
several groups have evaluated the feasibility of infusing NK
cells in haploidentical transplants. Recently, investigators
from Duke University, USA, have reported the feasibility of
NK cell infusion in 14 HLA matched and 16 mismatched
nonmyeloablative transplanted patients [50]. Single-step
NK cell enrichment by CD56+ selecting column through
ClinMACS system yielded approximately 90% of NK cells of
interest, with a low level of CD4 and CD8 cells responsible
for GVHD development. In the mismatched patients, the
median dose of CD3−CD56+ cells/kg and contaminating
CD3+CD56+ cells infused were 9.21 × 106/kg and 0.27 ×
106, respectively, without signiﬁcant toxicity. Only 1 patient
in the mismatched setting developed grade ≥3-4 acute
GVHD. Results of this study showed that enriched NK cells
infusion is safe and has the potential to improve immune
recovery and outcomes although it should be demonstrated
in randomized studies.
11.3. Role of DLI in Haploidentical Transplants. Posttrans-
plant donor lymphocyte infusion (DLI) provided direct and
potentGVLactivitytotreatrelapseinpatientsreceivingHLA
matched both related and unrelated transplants. Limited
number of patients who received haploidentical transplant
given unmodiﬁed DLI, both prophylactically and therapeu-
tically, does not permit to draw deﬁnite conclusion about
the relationship between cell dose, GVHD, and GVL eﬀect.
However, the use of unmodiﬁed DLI can cause lethal GVHD.
Various approaches have been developed to circumvent this,
including induction of anergy [39], add back of regulatory
T-cells [51], and transduction of donor lymphocytes with
suicide genes [52, 53].
Recently, Ciceri et al. [54] reported results of a non-
randomised phase I-II study on the use of suicide-gene-
engineered donor lymphocytes after haploidentical HSCT
for 28 patients with leukaemia. Patients were given escalat-
ing doses of donor lymphocytes expressing herpes-simplex
thymidine kinase suicide gene (TK-cells) starting at 28 days
after transplantation. Of the 28 patients infused, 22 (88%)
showed TK-cell engraftment who achieved CD3+ counts of
100cells/µL or more between 13 and 42 days from infusion.
Interestingly, the 6 patients without engraftment remained
immunodeﬁcient. Ten (45%) of 22 immune-reconstituted
patients developed grade 1–4 acute GVHD, and one devel-
oped extensive chronic GVHD. Ten patients needed ganci-
clovir treatment which resulted in a signiﬁcant reduction of
circulating TK-cells. No patient died from GVHD. Patients
showed normalization of cytomegalovirus and Epstein-Barr
virus- (EBV-) speciﬁc T-cell recovery within 3 months
of transplantation. Remarkably, in immune reconstituted
patients,progressivenormalisationofantiviralresponseswas
associated with decline in the number of infectious events as
compared with patients who failed immune reconstitution.
Consequently, the cumulative incidence of nonrelapse mor-
tality at 100 days was low, 14% (with infectious mortality
of 9%) in TK-treated immune-reconstituted patients versus
60% in nonimmune-reconstituted patients. The authors of
this study concluded that a good survival rate of 49%
observed in patients with de novo leukemias might be due
to the absence of post transplant immunosuppression and
early add back of TK-cells resulted in a reduced infectious
mortality. Results of this study showed feasibility and beneﬁt
from early TK-suicide-gene induced lymphocytes infusion
which resulted in fast immune reconstitution and decreased
nonrelapse mortality due to infection.
Amrolia et al. [55] used an anti-CD25 immunotoxin to
deplete alloreactive lymphocytes and infused allodepleted
donor T-cells after ex vivo T-cell depleted haploidentical
transplants. They demonstrated that viral-speciﬁc responses
were observed in 4 of 6 evaluable patients receiving higher
dosesofT-cells,withonlytwopatientsdevelopingsigniﬁcant
acute or chronic GVHD. Results of this study are very
promising in terms of prevention of sever GVHD, but this
beneﬁt was oﬀset by high leukaemia relapse (43%).
11.4. Role of T Regulatory Lymphocytes in Haploidenti-
cal Transplantation. Hoﬀmann et al. [56] showed that
CD4+CD25+ T-cells (Tregs) suppress GVHD in a murine
model of allogeneic BMT across a complete MHC class I and
II barrier. In a murine GVHD model, adoptive transfer of
Tregs resulted in abrogation of GVHD and enhancement of
immunereconstitution,henceprotectinganimalsfromlethal
CMV infection [57]. Recently, researchers from the Perugia
team have reported outcomes of haploidentical transplan-
tation in 28 patients with hematologic malignancies (AML
= 22, ALL = 5, NHL = 1) who received CD34+ selected
grafts and Tregs of infusion [58]. After conditioning with
TBI, thiotepa, ﬂudarabine, and cyclophosphamide patients
received fresh donor Tregs isolated by immunoselection on
day-4, and CD34+ selected cells (mean 9.4 × 106 ± 3.4/kg)
and conventional (Tcons) lymphocyte infusion on day 0. No
posttransplant immunosuppression was given. The ﬁrst 4
patients received 0.5 × 106/kg of Tcons and 2 × 106/kg of8 Bone Marrow Research
Tregs. The absence of GVHD allowed them to escalate Tcons
to 1 × 106/kg in the next 17 patients, while the dose of Tregs
remained unchanged. The last 5 patients received Tcons 2 ×
106/kg and Tregs 4 × 106/kg. Two patients did not receive
Tcons, because FoxP3+ expression in the Treg preparation
was <50%. Twenty four patients had sustained engraftment.
Two of 26 evaluable patients developed grade 2–4 acute
GVHD and none chronic GVHD. Both patients received
Tconsof2 ×106/kg.Patientshadrapidincreaseinperipheral
l y m p h o c y t e sw i t h1 0 0µLo fC D 4a n dC D 8c e l l sb e t w e e n2 8 –
135 and 19–95 days, respectively. There was early emergence
of speciﬁc CD4+ and CD8+ for pathogens as aspergillus,
candida, cytomegalovirus, adenovirus, herpes simplex virus,
varicella zoster virus, and toxoplasma as compared with
previous patients who received standard haploidentical
transplant. Thirteen patients died, 8 of them from infectious
complications although 4 patients had pretransplant fungal
infection. Only one patient had relapse. Results of this
study are very interesting and promising. Fewer incidence of
GVHD despite high doses of early unmodiﬁed donor lym-
phocyte infusion is impressive, indicating that donor Tregs
areabletoabrogateGVHDandfasterearlyimmunerecovery
which is a key problem in haploidentical transplantation.
11.5. Role of Photodepletion in Haploidentical Transplants.
Photodepletion of alloreactive T-cells is another approach
to overcome drawbacks of haploidentical T-cell depleted
transplants. Roy et al. [59] have reported on 19 patients
who received ex vivo T-cell depleted haploidentical trans-
plantation followed by administration of donor lymphocytes
photodepleted of alloreactive T-cells. None of the 12 patients
receiving high CD3+ cell doses (3.2 × 105 to 5.0 × 106/kg)
developed grade 2–4 GVHD, and 2-year survival rate was
82%.
12. Conclusion
Haploidentical transplants oﬀer a potential cure for patients
in need of allogeneic transplantation when an HLA-matched
either related or unrelated donor is not available. It is
a reasonable option for patients who do need urgent
transplantation or also for non-Caucasian patients, in whom
a chance of ﬁnding an unrelated matched donor is still low.
Recent advances with eﬀective T-cell depletion have made
it possible to perform haploidentical transplantation with a
high sustained engraftment rate, lower early post transplant
mortality and low rates of severe GVHD. However, poor
immune recovery with associated infectious complications
leading to late mortality, and relapse remain major obstacles
to overcome. Donor selection based on NIMA matching
or KIR typing and novel posttransplant cellular therapies
will allow to further improving transplant outcomes in
haploidentical transplants. Selective ex vivo or in vivo
T-cell depletion methods appear promising and might
be eﬀective in preserving tumor- and pathogen-speciﬁc
immunity while eliminating alloreactive T-cells responsible
for GVHD. The data presented in this paper demonstrate
important achievements made during the last decade in
the ﬁeld of haploidentical transplantation and great interest
of scientiﬁc community in promoting the ﬁeld with the
ultimate goal being to cure more patients in need of stem-
cell transplantation.
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